J Gen Virol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Gen Virol 68 (1987), 1457-1461; DOI 10.1099/0022-1317-68-5-1457
© 1987 Society for General Microbiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masuho, Y.
Right arrow Articles by Minamishima, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masuho, Y.
Right arrow Articles by Minamishima, Y.
Agricola
Right arrow Articles by Masuho, Y.
Right arrow Articles by Minamishima, Y.

Human Monoclonal Antibodies Neutralizing Human Cytomegalovirus

Yasuhiko Masuho1, Yoh-Ichi Matsumoto1, Tohru Sugano1, Shigeki Fujinaga1 and Yoichi Minamishima2

1 Teijin Institute for Biomedical Research, Asahigaoka, 4-3-2, Hino-city, Tokyo 191
and2 Department of Microbiology, Miyazaki Medical College, Miyazaki, Japan

Hybridomas producing human monoclonal antibodies (MAbs) against human cytomegalovirus (CMV) were generated by fusion of human spleen cells and mouse myeloma cells. Two of the six MAbs obtained neutralized viral infectivity even at concentrations lower than 1 µg/ml. One MAb required complement for neutralization but the other did not. Both MAbs recognized viral proteins of Mr 130000 and 55000. Furthermore, these neutralizing MAbs bound to the surface membrane of CMV-infected cells. These results suggest that human MAbs may provide a new means of passive immunization against CMV infection in humans.

Keywords: CMV, human monoclonal antibodies, neutralization

Received 30 September 1986; accepted 28 January 1987.


This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
J. Lantto, J. M. Fletcher, and M. Ohlin
A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B
J. Gen. Virol., August 1, 2002; 83(8): 2001 - 2005.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Klein, K. Schoppel, N. Amvrossiadis, and M. Mach
Strain-Specific Neutralization of Human Cytomegalovirus Isolates by Human Sera
J. Virol., February 1, 1999; 73(2): 878 - 886.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1987 by the Society for General Microbiology.